quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:46:18·41d
SECFiling
Corvus Pharmaceuticals Inc. logo

Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

CRVS· Corvus Pharmaceuticals Inc.
Health Care
Original source

Companies

  • CRVS
    Corvus Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 17UpdateGoldman$40.00
  • Oct 13UpdateBarclays$16.00
  • Jan 2UpdateH.C. Wainwright$11.00
  • Aug 18UpdateOppenheimer$7.00
  • Dec 3UpdateCantor Fitzgerald$8.00
  • Dec 1UpdateJefferies$8.00

Related

  • SEC12h
    Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
  • PR21h
    Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
  • PR2d
    Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
  • ANALYST6d
    Goldman initiated coverage on Corvus Pharmaceuticals with a new price target
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.
  • SEC41d
    SEC Form 424B5 filed by Corvus Pharmaceuticals Inc.
  • SEC41d
    SEC Form S-3ASR filed by Corvus Pharmaceuticals Inc.
  • SEC42d
    SEC Form 10-K filed by Corvus Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022